Texting patients could boost psoriasis drug success

NCT ID NCT05570955

Ongoing Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether weekly text reminders help people with psoriasis take their deucravacitinib medication as prescribed. Forty patients will be split into two groups: one gets reminders, the other does not. Researchers will interview participants to understand what helps or hinders sticking to the treatment, and compare skin improvement between those who take the drug regularly and those who don't.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: deucravacitinib
What this could lead to: If successful, this could show that simple text reminders help people take their psoriasis medication more consistently, leading to better real-world results.
What could go wrong: This is a small, early-stage study with only 40 participants, so findings may not apply to everyone. It focuses on adherence behavior, not on whether the drug itself works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Wake Forest University Health Sciences Department of Dermatology

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.